[Acute congestive heart failure due to Bevacizumab in metastatic breast cancer: a case report].
| Autor: | Akimana G; Service d'Oncologie Médicale, Institut National d'Oncologie, Rabat, Maroc., Onana R; Service d'Oncologie Médicale, Institut National d'Oncologie, Rabat, Maroc., Lkhooyali S; Service d'Oncologie Médicale, Institut National d'Oncologie, Rabat, Maroc., Errihani H; Service d'Oncologie Médicale, Institut National d'Oncologie, Rabat, Maroc. |
|---|---|
| Jazyk: | francouzština |
| Zdroj: | The Pan African medical journal [Pan Afr Med J] 2022 Sep 30; Vol. 43, pp. 50. Date of Electronic Publication: 2022 Sep 30 (Print Publication: 2022). |
| DOI: | 10.11604/pamj.2022.43.50.34743 |
| Abstrakt: | The addition of Bevacizumab to chemotherapy has shown its first-line interest in metastatic breast cancer by improving PFS but not OS. After a certain period of exposure, the appearance of side effects such as acute Congestive heart failure (CHF) has been described during clinical trials; manifested by a drop in LVEF and clinical signs which sometimes caused a hospitalization. We report the case of a patient in whom this exposure time was rather long with a very long survival under Bevacizumab. The onset of arterial hypertension appeared after 8 months of treatment with Bevacizumab in combination with metastatic first- line chemotherapy, while acute CHF occurred after approximately 10 years of treatment, which is at the 129 th treatment. The evolution of CHF was favorable after adequate treatment and discontinuation of Bevacizumab as in most cases reported in the literature. Competing Interests: Les auteurs ne déclarent aucun conflit d´interêts. (Copyright: Gloria Akimana et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|